Unexpectedly, TLSs were found in the tumor sites of the VEGF-C treatment group (Fig. 5h), which were further confirmed by multiplex immunofluorescence assay, indicating the presence of CD20+ B cells, CD3+ T cells and CD21+ follicular DCs, which were organized into lymphoid structures (Fig. 5i). Here, CR2 is linked to neoplasm.